Viral vectors as vaccine platforms: deployment in sight

Christine S. Rollier(University of Oxford), Adrian V. S. Hill(Jenner Institute), Katie Ewer(University of Oxford), Matthew G. Cottingham(University of Oxford), Arturo Reyes‐Sandoval(Instituto Politécnico Nacional)
Current Opinion in Immunology
April 22, 2011
10.1016/j.coi.2011.03.006
Cited by 207

Related Papers

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
|The Lancet|2020|5k
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
|The Lancet|2021|1.2k
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
|Nature Medicine|2020|643
Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial
|The Lancet|2001|528